SCHEMBL3765706

SCHEMBL3765706

O=C(NCC1C2CNCC21)c1cccc(C(C(F)(F)F)C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 1/20 0.43
PRMT5 O14744 1/20 0.40
TP53BP1 Q12888 1/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
ROCK2 O75116 6/20 0.37
GAA P10253 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
HPGD P15428 1/20 0.37
CYP2C19 P33261 1/20 0.37
GPR139 Q6DWJ6 1/20 0.37
ITGB3 P05106 1/20 0.37
ITGA2B P08514 1/20 0.37
OPRM1 P35372 1/20 0.36
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ROCK1 Q13464 2/20 0.36
TACR1 P25103 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3770029 0.85 CACNA1H (0.43) HDAC6PRMT5TP53BP1KMT2AMEN1
SCHEMBL5513102 0.81 POLB (0.56) TP53BP1ALDH1A1POLB
Hydrochloric Acid SCHEMBL709535 0.81 POLB (0.55) TP53BP1ALDH1A1POLB
SCHEMBL3783233 0.80 HDAC6 (0.44) HDAC6KMT2AMEN1ROCK2GAA
SCHEMBL5506383 0.79 NAMPT (0.51) HDAC6ROCK2HPGDGPR139OPRM1
Hydrochloric Acid SCHEMBL709982 0.78 NAMPT (0.50) HDAC6ROCK2GPR139OPRM1ROCK1
SCHEMBL15967359 0.77 OPRM1 (0.54) OPRM1
SCHEMBL708595 0.76 MEN1 (0.52) PRMT5KMT2AMEN1HPGDALDH1A1
Hydrochloric Acid SCHEMBL708457 0.76 OPRM1 (0.53) OPRM1POLB
SCHEMBL3765708 0.76 BCHE (0.33) PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1869019-B1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PROD INC (US) 2014-08-27 EP claimed
EP-1869019-A1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS Pfizer Products Incorporated (US) 2007-12-26 EP claimed
WO-2006106425-A1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PRODUCTS INC. (US) 2006-10-12 WO claimed
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors PFIZER INC. 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors SLC1A2, SLC1A1, SLC6A5 HDAC6 2873/4885PRMT5 900/4885TP53BP1 2986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.